Aggressive pituitary tumors in the young and elderly

被引:26
|
作者
Tatsi, Christina [1 ]
Stratakis, Constantine A. [1 ]
机构
[1] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Genet & Endocrinol, NIH, Clin Res Ctr, 10 Ctr Dr,Bldg 10,Room 1-3330,MSC1103, Bethesda, MD 20892 USA
来源
基金
美国国家卫生研究院;
关键词
Pituitary; Children; Adolescent; Aggressive; Adenoma; LINKED ACROGIGANTISM SYNDROME; GIANT PROLACTINOMAS; PHASE-II; CLINICAL CHARACTERISTICS; ADRENOCORTICAL-CELLS; GERMLINE MUTATIONS; EUROPEAN-SOCIETY; CUSHINGS-DISEASE; GENE-MUTATIONS; ADENOMAS;
D O I
10.1007/s11154-019-09534-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aggressive pituitary tumors (APTs) represent rare pituitary adenomas (PAs) with local invasion of surrounding tissues, increased risk for multiple recurrence, rapid tumor growth, or resistance to standard therapies. The most common APTs in children and adolescents are giant prolactinomas and somatotropinomas. Few cases of Crooke's cell adenomas, silent corticotroph adenomas and pituitary carcinomas have also been reported in the literature. Pediatric patients with APTs have higher risk of harboring germline genetic defects, most commonly in theMEN1andAIPgenes. Since certain genetic defects confer a more aggressive behavior to PAs, genetic testing should be considered in tumors with young onset and positive family history. The management of pediatric APTs involves usually a combination of standard therapies (surgical, medical, radiation). Newer agents, such as temozolomide, have been used in few cases of pediatric pituitary tumors with promising results. In the elderly, PAs are more commonly non-functioning. Their management often poses dilemmas given the coexistence of age-related comorbidities. However, standard surgical treatment and temozolomide seem to be safe and well tolerated in elderly patients.
引用
收藏
页码:213 / 223
页数:11
相关论文
共 50 条
  • [21] Medical Therapy of Aggressive Pituitary Tumors
    Petersenn, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2021, 129 (03) : 186 - 193
  • [22] Aggressive nonfunctioning pituitary neuroendocrine tumors
    Sérgio Portovedo
    Leonardo Vieira Neto
    Paula Soares
    Denise Pires de Carvalho
    Christina Maeda Takiya
    Leandro Miranda-Alves
    Brain Tumor Pathology, 2022, 39 : 183 - 199
  • [23] Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment
    Burman, Pia
    Casar-Borota, Olivera
    Perez-Rivas, Luis Gustavo
    Dekkers, Olaf M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (07): : 1585 - 1601
  • [24] Temozolomide for aggressive pituitary tumors:-A literature review
    Hui-zheng, Hu
    Lei, Lei
    ASIAN JOURNAL OF SURGERY, 2024, 47 (02) : 1300 - 1301
  • [25] Future treatment strategies of aggressive pituitary tumors
    Steven W. J. Lamberts
    Leo J. Hofland
    Pituitary, 2009, 12
  • [26] Future treatment strategies of aggressive pituitary tumors
    Lamberts, Steven W. J.
    Hofland, Leo J.
    PITUITARY, 2009, 12 (03) : 261 - 264
  • [27] The epidemiology of aggressive pituitary tumors (and its challenges)
    Olaf M. Dekkers
    Niki Karavitaki
    Alberto M. Pereira
    Reviews in Endocrine and Metabolic Disorders, 2020, 21 : 209 - 212
  • [28] PROLACTIN LEVELS IN AGGRESSIVE PITUITARY-TUMORS
    VASSILOUTHIS, J
    RICHARDSON, AE
    JOURNAL OF NEUROSURGERY, 1980, 53 (01) : 131 - 132
  • [29] Aggressive and resistant-to-treatment pituitary tumors
    Cuny, T.
    Chanson, P.
    ANNALES D ENDOCRINOLOGIE, 2013, 74 : S3 - S12
  • [30] The role of temozolomide in the treatment of aggressive pituitary tumors
    Liu, James K.
    Patel, Jimmy
    Eloy, Jean Anderson
    JOURNAL OF CLINICAL NEUROSCIENCE, 2015, 22 (06) : 923 - 929